Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
NCT03862716 on ClinicalTrials.gov · last registry update 2023-10-25
A small phase 3 — 159 participants, against a typical 424. The sponsor logged completion for 15 June 2022. Primary outcome, as filed: Proportion of participants achieving drug-free diabetes remission. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Population Health Research Institute
- Sponsor type
- Other
- Enrollment
- 159
- Started
- 2019-04-23
- Primary completion
- 2022-06-15 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Proportion of participants achieving drug-free diabetes remission
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.